Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Loxo Oncology Inc. (LOXO): OrbiMed Advisors Reports Percentage of Ownership Change

Page 1 of 12

Samuel Isaly’s OrbiMed Advisors recently filed a 13D filing with the SEC in which it reported owning 2.18 million common shares of Loxo Oncology Inc. (NASDAQ:LOXO), which account for 10.04% of the company’s outstanding stock. Although the number of shares owned by Orbimed Advisors hasn’t changed, the filing was submitted in order to report a change in the percentage of shares that it owns, due to the amount of outstanding shares increasing. Previously, the 2.18 million shares owned by OrbiMed Advisors amassed 11.12% of the company’s outstanding stock.

Loco Oncology is a biopharmaceutical company that works on discovering various therapeutics to help treat people with genetically defined cancer. One such treatment is LOXO 101, which recently received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Over the last 12 months, the company’s shares have gained 37.13%. For the second quarter of 2016, the company reported a net loss of $15.92 million amounting to a net loss per share of $0.77, compared to a net loss of $8.06 million or $0.49 per share for the same quarter of the previous year. 

Samuel Isaly Orbimed Advisors

As per Insider Monkey’s hedge fund database of 766 13F-filing hedge funds, at the end of the first quarter of 2016, 14 of those investors were long the stock, down from 18 a quarter earlier. The largest position was reported by Dennis Purcell’s Aisling Capital, worth close to $103.8 million, while the second-biggest stake was held by Orbimed Advisors. Some other smart money managers with similar bullishness included Phill Gross and Robert Atchinson’s Adage Capital Management, Richard Driehaus’ Driehaus Capital, and Zach Schreiber’s Point State Capital.

Among investors who lost interest in Loxo Oncology (NASDAQ:LOXO) and decided to sell their shares during the first quarter were Jacob Gottlieb’s Visium Asset Management, which said goodbye to its position worth about $11.4 million in stock, and Dmitry Balyasny’s Balyasny Asset Management, which sold off a position worth about $0.8 million.

Follow Loxo Oncology Inc. (NASDAQ:LOXO)
Trade (NASDAQ:LOXO) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 2,175,857 0 2,175,857 2,175,857 10.04%
OrbiMed Capital GP V 0 2,175,857 0 2,175,857 2,175,857 10.04%
Samuel D. Isaly 0 2,175,857 0 2,175,857 2,175,857 10.04%

Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Page 1 of 12 – SEC Filing



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*

LOXO ONCOLOGY, INC.


(Name of Issuer)

COMMON STOCK


(Title of Class of Securities)
548862101
(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
Samuel D. Isaly
         
601 Lexington Avenue, 54th Floor
New York, NY 10022

Telephone:  (212) 739-6400


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 3, 2016


(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 12

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!